Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR

Molecular Metabolism

Volumn 9, Issue , 2018, Pages 131-140

  Jadhav, Kavita ^a   Xu, Yang ^a   Xu, Yanyong ^a   Li, Yuanyuan ^a   Xu, Jiesi ^a,b   Zhu, Yingdong ^a   Adorini, Luciano ^c   Lee, Yoon Kwang ^a   Kasumov, Takhar ^d   Yin, Liya ^a   Zhang, Yanqiao ^a  

^a Northeastern Ohio Medical University   (United States)

^b INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^c INTERCEPT PHARMACEUTICALS   (United States)

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Farnesoid X receptor; NAFLD; Obesity; TGR5

Indexed keywords

APOLIPOPROTEIN E; CCAAT ENHANCER BINDING PROTEIN ALPHA; FARNESOID X RECEPTOR; G PROTEIN COUPLED BILE ACID RECEPTOR; G PROTEIN COUPLED RECEPTOR; HETERODIMER; HORMONE RECEPTOR STIMULATING AGENT; INT 767; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL HETERODIMER PARTNER; UNCLASSIFIED DRUG; 6-ETHYL-24-NORCHOLANE-3,7,23-TRIOL-23 SULFATE; BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GPBAR1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CEBP ALPHA GENE; CONTROLLED STUDY; DRUG MECHANISM; ENERGY EXPENDITURE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID METABOLISM; LIPOGENESIS; MALE; METABOLIC DISORDER; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PPAR GAMMA GENE; PRIORITY JOURNAL; PROTEIN TRANSPORT; AGONISTS; ANIMAL; C57BL MOUSE; HEP-G2 CELL LINE; HUMAN; LIPID DIET; METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; DIET, HIGH-FAT; HEP G2 CELLS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85040536846     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2018.01.005     Document Type: Article

References (45)

1. Li, Y., Jadhav, K., Zhang, Y., Bile acid receptors in non-alcoholic fatty liver disease. Biochemical Pharmacology 86 (2013), 1517–1524.
2. Angulo, P., Nonalcoholic fatty liver disease. New England Journal of Medicine 346 (2002), 1221–1231.
3. Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits”?. Gastroenterology 114 (1998), 842–845.
4. Farrell, G.C., Larter, C.Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006), S99–S112.
5. Francque, S.M., van der Graaff, D., Kwanten, W.J., Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. Journal of Hepatology 65 (2016), 425–443.
6. Potze, W., Siddiqui, M.S., Sanyal, A.J., Vascular disease in patients with nonalcoholic fatty liver disease. Seminars in Thrombosis and Hemostasis 41 (2015), 488–493.
7. Byrne, C.D., Targher, G., NAFLD: a multisystem disease. Journal of Hepatology 62 (2015), S47–S64.
8. Armstrong, M.J., Adams, L.A., Canbay, A., Syn, W.K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
9. Lee, F.Y., Lee, H., Hubbert, M.L., Edwards, P.A., Zhang, Y., FXR, a multipurpose nuclear receptor. Trends in Biochemical Sciences 31 (2006), 572–580.
10. Zhang, Y., Kast-Woelbern, H.R., Edwards, P.A., Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. Journal of Biological Chemistry 278 (2003), 104–110.
11. Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochemical and Biophysical Research Communications 298 (2002), 714–719.
12. Pols, T.W., Noriega, L.G., Nomura, M., Auwerx, J., Schoonjans, K., The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. Journal of Hepatology 54 (2011), 1263–1272.
13. Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., Staels, B., Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews 89 (2009), 147–191.
14. Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 10 (2009), 167–177.
15. Watanabe, M., Houten, S.M., Mataki, C., Christoffolete, M.A., Kim, B.W., Sato, H., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006), 484–489.
16. Pols, T.W., Nomura, M., Harach, T., Lo Sasso, G., Oosterveer, M.H., Thomas, C., et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metabolism 14 (2011), 747–757.
17. Watanabe, M., Horai, Y., Houten, S.M., Morimoto, K., Sugizaki, T., Arita, E., et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. Journal of Biological Chemistry 286 (2011), 26913–26920.
18. Rizzo, G., Passeri, D., De Franco, F., Ciaccioli, G., Donadio, L., Rizzo, G., et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Molecular Pharmacology 78 (2010), 617–630.
19. McMahan, R.H., Wang, X.X., Cheng, L.L., Krisko, T., Smith, M., El Kasmi, K., et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. Journal of Biological Chemistry 288 (2013), 11761–11770.
20. Miyazaki-Anzai, S., Masuda, M., Levi, M., Keenan, A.L., Miyazaki, M., Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One, 9, 2014, e108270.
21. Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G., Gonzalez, F.J., Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 (2000), 731–744.
22. Vassileva, G., Golovko, A., Markowitz, L., Abbondanzo, S.J., Zeng, M., Yang, S., et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochemical Journal 398 (2006), 423–430.
23. Wang, L., Lee, Y.K., Bundman, D., Han, Y., Thevananther, S., Kim, C.S., et al. Redundant pathways for negative feedback regulation of bile acid production. Developmental Cell 2 (2002), 721–731.
24. Bligh, E.G., Dyer, W.J., A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology 37 (1959), 911–917.
25. Xu, J., Li, Y., Chen, W.D., Xu, Y., Yin, L., Ge, X., et al. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology 59 (2014), 1761–1771.
26. Xu, Y., Zalzala, M., Xu, J., Li, Y., Yin, L., Zhang, Y., A metabolic stress-inducible miR-34a-HNF4alpha pathway regulates lipid and lipoprotein metabolism. Nature Communications, 6, 2015, 7466.
27. Brunengraber, D.Z., McCabe, B.J., Kasumov, T., Alexander, J.C., Chandramouli, V., Previs, S.F., Influence of diet on the modeling of adipose tissue triglycerides during growth American journal of physiology. Endocrinology and Metabolism 285 (2003), E917–E925.
28. Zhang, Y., Lee, F.Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F.J., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proceedings of the National Academy of Sciences of the United States of America 103 (2006), 1006–1011.
29. Zhang, Y., Wang, X., Vales, C., Lee, F.Y., Lee, H., Lusis, A.J., et al. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arteriosclerosis, Thrombosis, and Vascular Biology 26 (2006), 2316–2321.
30. Zhang, Y., Ge, X., Heemstra, L.A., Chen, W.D., Xu, J., Smith, J.L., et al. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Molecular Endocrinology 26 (2012), 272–280.
31. Li, Y., Zalzala, M., Jadhav, K., Xu, Y., Kasumov, T., Yin, L., et al. Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice. Hepatology 63 (2016), 1860–1874.
32. Yu, S., Matsusue, K., Kashireddy, P., Cao, W.Q., Yeldandi, V., Yeldandi, A.V., et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. Journal of Biological Chemistry 278 (2003), 498–505.
33. Schadinger, S.E., Bucher, N.L., Schreiber, B.M., Farmer, S.R., PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. American Journal of Physiology - Endocrinology and Metabolism 288 (2005), E1195–E1205.
34. Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation 109 (2002), 1125–1131.
35. Qiao, L., MacLean, P.S., You, H., Schaack, J., Shao, J., Knocking down liver ccaat/enhancer-binding protein alpha by adenovirus-transduced silent interfering ribonucleic acid improves hepatic gluconeogenesis and lipid homeostasis in db/db mice. Endocrinology 147 (2006), 3060–3069.
36. Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H., Krieger, M., Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996), 518–520.
37. Zhang, Y., Yin, L., Anderson, J., Ma, H., Gonzalez, F.J., Willson, T.M., et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. Journal of Biological Chemistry 285 (2010), 3035–3043.
38. Bavner, A., Sanyal, S., Gustafsson, J.A., Treuter, E., Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends in Endocrinology and Metabolism 16 (2005), 478–488.
39. Lee, Y.K., Dell, H., Dowhan, D.H., Hadzopoulou-Cladaras, M., Moore, D.D., The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression. Molecular and Cellular Biology 20 (2000), 187–195.
40. Zhang, Y., Farnesoid X receptor-Acting through bile acids to treat metabolic disorders. Drugs of the Future 35 (2010), 635–642.
41. Xu, Y., Li, F., Zalzala, M., Xu, J., Gonzalez, F.J., Adorini, L., et al. FXR activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption. Hepatology 64 (2016), 1072–1085.
42. Moraes, L.A., Unsworth, A.J., Vaiyapuri, S., Ali, M.S., Sasikumar, P., Sage, T., et al. Farnesoid X receptor and its ligands inhibit the function of platelets. Arteriosclerosis, Thrombosis, and Vascular Biology 36 (2016), 2324–2333.
43. Vassileva, G., Hu, W., Hoos, L., Tetzloff, G., Yang, S., Liu, L., et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. Journal of Endocrinology 205 (2010), 225–232.
44. Cyphert, H.A., Ge, X., Kohan, A.B., Salati, L.M., Zhang, Y., Hillgartner, F.B., Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. Journal of Biological Chemistry 287 (2012), 25123–25138.
45. Perez, A., Thuillard, J.L., Bentzen, C.L., Niesor, E.J., Expression of nuclear receptors and apo E secretion during the differentiation of monocytic THP-1 cells into macrophages. Cell Biology and Toxicology 19 (2003), 95–105.